Effect Of Ethanolic Extracts Of Andrographis Paniculata On Type 2 Diabetes Mellitus And Insulin Resistant Rats by Rammohan, Subramanian
EFFECT OF ETHANOLIC EXTRACTS OF 
ANDROGRAPHIS PANICULATA ON TYPE 2 
DIABETES MELLITUS AND INSULIN 
RESISTANT RATS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUBRAMANIAN RAMMOHAN 
 
 
 
 
 
 
 
 
 
 
 
 
UNIVERSITI SAINS MALAYSIA 
 
2009 
EFFECT OF ETHANOLIC EXTRACTS OF ANDROGRAPHIS PANICULATA 
ON TYPE 2 DIABETES MELLITUS AND INSULIN RESISTANT RATS 
  
 
 
 
 
 
 
 
 
 
 
 
 
by 
 
 
 
 
 
 
 
 
 
 
 
SUBRAMANIAN RAMMOHAN 
 
 
 
 
 
 
 
 
 
 
 
 
Thesis submitted in fulfillment of the  
requirements for the degree of 
Doctor of Philosophy 
 
 
 
 
 
February 2009 
 ii 
ACKNOWLEDGEMENTS 
 
 
I would like to express my utmost and deepest gratitude and appreciation to 
my wonderful supervisor Prof. Dr. Mohd. Zaini Asmawi for his towering presence, 
continuous effort, guidance, and patience. His valuable experience was of 
tremendous help and was always a source of ideas. My constant discussions were 
always fruitful and has a played an important role in making this thesis a reality. 
 
 My heartfelt gratitude and appreciation goes to my Co-supervisor, Assoc. 
Prof. Dr. Amirin Sadikun who had helped a lot with valuable inputs with regard to 
extraction and conduct of analytical experiment. Without his contribution this thesis 
would have been incomplete. 
 
I am most grateful to my parents, brother and sister-in-law for their love, 
support, kindness, understanding, and above all their patience which always provided 
me the necessary drive and inspiration to work hard. 
 
My sincere thanks and appreciation to my Harapan friends Venkat, Ravi, and 
Rahamath and who have stood by me during times of joy and frustration and have 
always extended a helping hand to me during the duration of my stay. Thanks are 
also due to my friends Mahfoudh, Yam, Ali, Mokhtar, Khalid, and Omar with whom 
I have spent considerable time in lab and were like family. 
 
I also take this opportunity to express my gratitude and appreciation to my lab 
technician Mr. Roseli Hassan. He has extended all possible help and has always 
made my lab work easier. Thanks are also due to Mrs. Yong, Mr. Wan, Mr. 
 iii 
Shamsuddin, Mr. Tan, and other technicians and staff members of School of 
Pharmaceutical Sciences who one way or other contributed either directly or 
indirectly throughout the duration of research. 
  
Lastly I would like to express my appreciation to Ministry of Science, 
Technology, and Environment for the research grant 304/PFARMASI/640043/k105 
and 304/ PFARMASI/6123003 also to Universiti Sains Malaysia for granting me the 
USM Fellowship. 
 
 
 
  
 
 
 
Subramanian Rammohan 
February 2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iv 
                                          TABLE OF CONTENTS                                                  
                                                                                                                                 Page             
ACKNOWLEDGEMENTS ii 
TABLE OF CONTENTS iv 
LIST OF TABLES x 
LIST OF FIGURES xiii 
LIST OF ABBREVIATION & SYMBOLS xv 
ABSTRAK xx 
ABSTRACT xxiii 
PUBLICATIONS/CONFERENCES xxv 
 
 
CHAPTER 1 : INTRODUCTION 
 
1.0 Type 2 diabetes and insulin resistance 1 
1.1 Current scenario in Malaysia 2 
1.2 Pathophysiology of type 2 diabetes mellitus  3 
1.3 Clinical features of type 2 diabetes mellitus 6 
1.4 Insulin resistance 7 
1.5 Causative factors of insulin resistance 8 
1.6 Pathogenesis of insulin resistance            9 
1.7 Drug therapy in the treatment of type 2 diabetes mellitus and insulin 
resistance                                                                                              
      
          10 
1.8 Problems of anti-diabetic therapy 12 
1.9 Current drugs in the pipeline 13 
 
1.9.1 Exenatide 13 
 
1.9.2            Pramlintide 14 
 
1.9.3 Rimonabant 15 
 1.9.4 Vildagliptin            16 
 1.9.5 Ruboxistaurin 16 
 1.9.6 Sitagliptin 
 
17 
 v 
CHAPTER 2: REVIEW OF LITERATURE           
                                          
2.0 Andrographis paniculata 19 
2.1 Classification   19 
2.2 Botanical description  19 
2.3 Literature on Andrographis paniculata 21 
2.4 Current research status of Andrographis paniculata 
with respect to type 2 diabetes and insulin resistance 
29 
CHAPTER 3: PREPARATION OF ETHANOLIC EXTRACTS OF   
                        Andrographis paniculata                                               
 
3.0 Introduction 36 
3.1 Objectives  38 
3.2 Materials and Methods 38 
 3.2.1 Plant material and preparation of extracts 38 
3.3 Results 39 
 
3.3.1. Yield of extracts 39 
3.4 Discussion  39 
CHAPTER 4: HIGH PERFORMANCE LIQUID CHROMATOGRAPHY  
                         OF ETHANOLIC EXTRACTS OF Andrographis    paniculata AND  
                         ANDROGRAPHOLIDE   
                       
4.0 Introduction 41 
4.1 Objectives 44 
4.2 Materials and Methods 44 
 4.2.1 Plant material and preparation of extracts 44 
 
4.2.2 Chemicals 44 
4.3 Instrumentation and Chromatographic conditions 44 
4.4 Preparation of stock and working standard solution 45 
4.5 Absorption spectrum of andrographolide 45 
4.6 Preparation of calibration standards 45 
4.7 4.7.1 Linearity 46 
 4.7.2 Accuracy and  Precision  46 
 4.7.3 Limit of Detection and Limit of Quantitation 47 
 vi 
 
4.7.4 System suitability studies 47 
4.8 Results 48 
 
4.8.1. Absorption spectrum of AG 48 
 
4.8.2. Linearity 49 
 
4.8.3. Accuracy and  Precision 50 
 
4.8.4. Limit of Detection and Limit of Quantitation 50 
 
4.8.5. System suitability studies 50 
 
4.8.6. HPLC analysis 52 
4.9 Discussion 54 
CHAPTER 5 : PRE TREATMENT PROTECTIVE EFFECTS, DOSE FINDING STUDIES, 
                          AND INTRAPERITONEAL GLUCOSE TOLERANCE TEST ON  
                          ETHANOLIC EXTRACTS OF Andrographis paniculata  
 
5.0 Introduction 56 
5.1 Objectives 57 
5.2 Materials and Methods 57 
 5.2.1 Plant material and preparation of extracts 57 
 5.2.2 Experimental animals 58 
 5.2.3 Blood sample collection and determination of blood 
glucose 
58 
 5.2.4 Chemicals and drugs used 58 
 5.2.5 Experimental setup 59 
  5.2.5.1 Pre treatment protective effect of 
ethanolic extracts of Andrographis 
paniculata 
59 
  5.2.5.2 Dose finding studies of ethanolic 
extracts of Andrographis paniculata 
60 
  5.2.5.3 Intraperitoneal glucose tolerance test 61 
5.3 Statistical analysis 61 
5.4 Results 62 
 
5.4.1. Pretreatment protective effects of ethanolic extracts of 
Andrographis  paniculata 
62 
 
5.4.2. Dose finding studies of ethanolic extracts of Andrographis 
paniculata 
66 
 
5.4.3. Intraperitoneal glucose tolerance test in normal rats 
(IPGTT) 
70 
 vii 
5.5 Discussion 
 
73 
CHAPTER 6: IN VITRO AND IN VIVO ENZYME INHIBITION STUDIES 
 
6.0 Introduction 79 
6.1 Objectives 81 
6.2 In vitro alpha glucosidase inhibition studies 81 
 6.2.1 Materials and Methods 81 
  6.2.1.1 Plant materials and preparation of 
extracts 
81 
  6.2.1.2 Chemicals 81 
  6.2.1.3 Preparation of solutions 82 
  6.2.1.4 Experimental setup 84 
6.3 In vitro alpha amylase inhibition studies 84 
 6.3.1 Materials and Methods 84 
  6.3.1.1 Plant material and preparation of 
extracts 
84 
  6.3.1.2 Chemicals 84 
  6.3.1.3 Preparation of solutions 85 
  
6.3.1.4 Experimental setup 86 
6.4 In vivo alpha glucosidase inhibition studies in diabetic rats 87 
 6.4.1 Materials and Methods 87 
  6.4.1.1 Plant material and preparation of 
extracts 
87 
  
6.4.1.2 Experimental animals 87 
 6.4.2 Oral carbohydrate tolerance tests 88 
  6.4.2.1 Oral starch tolerance test 88 
  6.4.2.2 Oral sucrose test 89 
  6.4.2.3 Oral glucose test 89 
6.5 Statistical analysis 89 
6.6 Results 90 
 
6.6.1. In vitro alpha glucosidase inhibition studies 90 
 
6.6.2. In vitro alpha amylase inhibition studies 91 
 
6.6.3. In vivo alpha glucosidase inhibition studies in diabetic rats 95 
6.7 Discussion 117 
 viii 
 
 
CHAPTER 7: EFFECT OF ETHANOLIC EXTRACTS OF Andrographis paniculata  
                         ON LIVER GLYCOLYTIC, GLUCONEOGENIC, AND LIPOGENIC  
                         ENZYMES IN CHRONIC TYPE 2 DIABETIC RATS   
                                      
7.0 Introduction          124 
7.1 Objectives 126 
7.2 Materials and Methods 127 
 7.2.1 Plant material and preparation of extracts 127 
 7.2.2 Animals 127 
 
7.2.3 Oral glucose tolerance test 127 
 7.2.4 Induction of type 2 diabetic rats 128 
 7.2.5 Experimental Design 128 
  
7.2.6 Sample collection         129 
 
7.2.7 Analytical Methods 130 
  
 7.2.7.1 Determination of fasting serum 
glucose 
130 
 
 7.2.7.2 Determination of serum cholesterol, 
triglycerides, and free fatty acids 
130 
 
 7.2.7.3 Determination of liver carbohydrates 
metabolic enzymes 
131 
  7.2.7.4 Determination of liver antioxidant 
parameters 
131 
  7.2.7.5 Determination of serum insulin and 
liver glycogen 
131 
7.3 Calculation of Specific activity 131 
7.4 Statistical analysis 131 
7.5 Results 132 
 
7.5.1. Oral glucose tolerance test in normal rats 132 
 
7.5.2.  Body Weight changes 134 
 
7.5.3. Fasting serum glucose 137 
 
7.5.4. Serum cholesterol, triglyceride, and free fatty acids 138 
 
7.5.5. Liver carbohydrate metabolizing enzymes 142 
 
7.5.6. Liver protein levels 145 
 
7.5.7. Liver antioxidant parameters 147 
 
7.5.8. Serum insulin and liver glycogen 150 
7.6 Discussion          153 
 ix 
CHAPTER 8: EFFECT OF ETHANOLIC EXTRACTS OF Andrographis paniculata IN  
                        CHRONIC INSULIN RESISTANT RATS 
 
8.0 Introduction 163 
8.1 Measurement of insulin and insulin resistance 165 
8.2 Models of insulin resistance 168 
8.3 Objectives 169 
8.4 Materials and Methods 169 
 
8.4.1 Plant material and preparation of extracts 169 
 
8.4.2 Chemicals 169 
 8.4.3 Preparation of fat emulsion 170 
 8.4.4 Experimental animals           170 
 8.4.5 Measurement of the glucose-insulin index 171 
 8.4.6 Intraperitoneal glucose tolerance test 171 
 8.4.7 Tolbutamide-induced hypoglycemic challenge test 172 
 8.4.8 Insulin sensitivity test 173 
 8.4.9.  Experimental scheme 174 
8.5 Statistical analysis 175 
8.6 Results 175 
 
8.6.1.  Body weights 175 
 
8.6.2. Measurement of Glucose-insulin index and IPGTT 178 
 
8.6.3. Tolbutamide-induced hypoglycemic challenge test 190 
 
8.6.4. Insulin sensitivity test 196 
8.7 Discussion 204 
CHAPTER 9 : SUMMARY  
 
209 
CHAPTER 10 : FUTURE SCOPE OF WORK 
 
213 
REFERENCES 
 
216 
 
 
 
 
 
 x 
LIST OF TABLES 
 
          Page 
4.1  Summary of HPLC methods for determination of AG and other   
 andrographolides 
                                                                             
42 
4.2  Linearity parameters for AG 
 
50 
4.3  Intra-day and Inter-day accuracy and precision of AG 
 
51 
4.4 System suitability parameters 
 
52 
5.1 Pre treatment protective effects of 20%v/v ethanolic extract of 
Andrographis  paniculata 
 
64 
5.2 Pre treatment protective effects of 95%v/v ethanolic extract of 
Andrographis  paniculata 
 
65 
5.3 Dose finding studies of  20%v/v ethanolic extract of Andrographis 
paniculata                                                             
 
67 
5.4 Dose finding studies of  95%v/v ethanolic extract of Andrographis 
paniculata 
 
69 
6.1 Percentage inhibition of ethanolic extracts of Andrographis  
paniculata on in vitro alpha glucosidase enzyme.                         
 
92 
6.2 IC50 values for in vitro alpha glucosidase inhibition of ethanolic 
extracts of Andrographis  paniculata 
 
93 
6.3 Percentage inhibition of ethanolic extracts of Andrographis paniculata 
on in vitro alpha amylase enzyme 
 
94 
6.4 IC50 values for in vitro alpha amylase inhibition of ethanolic extracts 
of Andrographis  paniculata 
. 
95 
6.5 Effect of 20%v/v ethanolic extract of Andrographis  paniculata on 
PBG and AUC after starch loading in normal and diabetic rats 
 
97 
6.6 Effect of oral administration of 20%v/v ethanolic extract of 
Andrographis paniculata on blood glucose level of normal and 
diabetic rats loaded with 3 g/kg starch.   
 
98 
6.7 Effect of 95%v/v ethanolic extract of Andrographis  paniculata on 
PBG and AUC after starch loading in normal and diabetic rats 
 
101 
6.8 Effect of oral administration of 95%v/v ethanolic extract of 
Andrographis paniculata on blood glucose level of normal and 
diabetic rats loaded with 3 g/kg starch.   
 
102 
 xi 
6.9 Effect of 20%v/v ethanolic extract of Andrographis  paniculata on 
PBG and AUC after sucrose loading in normal and diabetic rats  
 
105 
6.10 Effect of oral administration of 20%v/v ethanolic extract of 
Andrographis paniculata on blood glucose level of normal and 
diabetic rats loaded with 4 g/kg sucrose.  
 
106 
6.11 Effect of 95%v/v ethanolic extract of Andrographis  paniculata on 
PBG and AUC after sucrose loading in normal and diabetic rats  
 
109 
6.12 Effect of oral administration of 95%v/v ethanolic extract of 
Andrographis paniculata on blood glucose level of normal and 
diabetic rats loaded with 4 g/kg sucrose.  
 
110 
6.13 Effect of 20%v/v ethanolic extract of Andrographis  paniculata on 
PBG and AUC after glucose loading in normal and diabetic rats  
 
112 
6.14 Effect of oral administration of 20%v/v ethanolic extract of 
Andrographis paniculata on blood glucose level of normal and 
diabetic rats loaded with 4 g/kg glucose.  
 
113 
6.15 Effect of 95%v/v ethanolic extract of Andrographis  paniculata on 
PBG and AUC after glucose loading in normal and diabetic rats  
 
115 
6.16 Effect of oral administration of 95%v/v ethanolic extract of 
Andrographis paniculata on blood glucose level of normal and 
diabetic rats loaded with 4 g/kg glucose.  
 
116 
7.1 Effect of daily administration of 20%v/v ethanolic extract for 21 days 
on liver carbohydrate metabolizing enzymes  
 
143 
7.2 Effect of daily administration of 95%v/v ethanolic extract for 21 days 
on liver carbohydrate metabolizing enzymes  
 
144 
7.3 Effect of daily administration of 20%v/v ethanolic extract for 21 days 
on liver antioxidant levels       
                                                  
148 
7.4 Effect of daily administration of 95%v/v ethanolic extract for 21 days 
on liver antioxidant levels       
 
149 
7.5 Effect of daily administration of 20%v/v ethanolic extract for 21 days 
on serum insulin and liver glycogen levels 
 
151 
7.6 Effect of daily administration of 95%v/v ethanolic extract for 21 days 
on serum insulin and liver glycogen levels 
 
152 
8.1 Serum glucose responses during the intraperitoneal glucose tolerance 
test (IPGTT) administered 20%v/v ethanolic extract of Andrographis 
paniculata. 
180 
 xii 
8.2 Serum glucose responses during the intraperitoneal glucose tolerance 
test (IPGTT) administered 95%v/v ethanolic extract of Andrographis 
paniculata. 
186 
8.3 Effect of tolbutamide on serum glucose, insulin levels and serum 
glucose lowering activity pretreated with 20%v/v ethanolic extract 
during tolbutamide-induced hypoglycemic challenge test      
  
192 
8.4 Effect of tolbutamide on serum glucose, insulin levels and serum 
glucose lowering activity pretreated with 95%v/v ethanolic extract 
during tolbutamide-induced hypoglycemic challenge test  
 
   195 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xiii
LIST OF FIGURES 
               Page                    
1.1 Pathogenesis of type 2 diabetes mellitus 
 
4 
1.2 Clinical abnormalities in insulin resistance 
 
8 
1.3 Mechanism of action of oral antidiabetic drugs    
 
11 
2.1 Leaves and aerial parts of Andrographis  paniculata 
 
20 
4.1 Absorption scan of andrographolide from 400-800 nm showing λmax at 
223 nm 
                                                                                    
49 
4.2 Standard calibration curve of AG 
                                                     
49 
4.3 A representative chromatogram of 20%v/v ethanolic extract of 
Andrographis paniculata   
                                                                  
52 
4.4 A representative chromatogram of 95%v/v ethanolic extract of 
Andrographis paniculata   
                                                                  
53 
4.5 A representative chromatogram of pure commercial AG 
 
53 
5.1 Effect of 20%v/v ethanolic extract of Andrographis paniculata on 
intraperitoneal glucose tolerance test in normal rats  
    
71 
5.2 Effect of 95%v/v ethanolic extract of Andrographis paniculata on 
intraperitoneal glucose tolerance test in normal rats  
 
72 
7.1 Effect of oral administration of 20%v/v ethanolic extract of 
Andrographis paniculata on blood glucose level of rats loaded with 
2gm/kg glucose po during oral glucose tolerance test 
 
133 
7.2 Effect of oral administration of 95%v/v ethanolic extract of 
Andrographis paniculata on blood glucose level of rats loaded with 
2gm/kg glucose po during oral glucose tolerance test 
    
134 
7.3 Effect of daily oral administration of 20%v/v ethanolic extract for 
21days on body weight of type 2 diabetic rats 
 
135 
7.4 Effect of daily oral administration of 95%v/v ethanolic extract for 
21days on body weight of type 2 diabetic rats                                   
 
136 
7.5 Effect of daily oral administration of 20%v/v ethanolic extract for 21 
days on weekly fasting serum glucose levels 
 
137 
7.6 Effect of daily oral administration of 95%v/v ethanolic extract for 21 
days on weekly fasting serum glucose levels                          
 
138 
 xiv 
7.7 Effect of daily administration of 20%v/v ethanolic extract for 21 days 
on serum cholesterol, triglycerides, and free fatty acids 
 
140 
7.8 Effect of daily administration of 95%v/v ethanolic extract for 21 days 
on serum cholesterol, triglycerides, and free fatty acids  
 
141 
7.9 (a) Effect of daily administration of 20%v/v ethanolic extract for 21 days 
on liver protein                                                                
 
145 
7.9 (b) Effect of daily administration of 95%v/v ethanolic extract for 21 days 
on liver protein                                                                
 
146 
8.1 Body weight changes of rats administered 20%v/v ethanolic extract of 
Andrographis paniculata  after 30 days treatment                              
 
176 
8.2 Body weight changes of rats administered 95%v/v ethanolic extract of 
Andrographis paniculata  after 30 days treatment     
 
177 
8.3 Serum insulin responses during the intraperitoneal glucose tolerance 
test (IPGTT) in insulin resistant rats administered 20%v/v ethanolic 
extract of Andrographis paniculata 
 
181 
8.4 Incremental areas under the curves (AUC) for serum levels of glucose 
and insulin in rats administered 20%v/v ethanolic extract of 
Andrographis paniculata during IPGTT 
 
182 
8.5 Glucose-insulin index calculated as the product of the serum glucose 
AUC and serum insulin AUC in rats administered 20%v/v ethanolic 
extract of Andrographis paniculata                                                       
 
183 
8.6 Serum insulin responses during the intraperitoneal glucose tolerance 
test (IPGTT) in insulin resistant rats administered 95%v/v ethanolic 
extract of Andrographis paniculata 
 
187 
8.7 Incremental areas under the curves (AUC) for serum levels of glucose 
and insulin in rats administered 95%v/v ethanolic extract of 
Andrographis paniculata during IPGTT 
 
188 
8.8 Glucose-insulin index calculated as the product of the serum glucose 
AUC and serum insulin AUC in rats administered 95%v/v ethanolic 
extract of Andrographis paniculata                                                       
 
189 
8.9 Effect of 20%v/v ethanolic extract of Andrographis paniculata on 
insulin sensitivity test in streptozotocin-induced diabetic rats          
 
199 
8.10 Effect of 95%v/v ethanolic extract of Andrographis paniculata on 
insulin sensitivity test in streptozotocin-induced diabetic rats    
 
203 
 
 
 xv 
LIST OF ABBREVIATIONS AND SYMBOLS 
 
 
 
% = percentage 
 
°C = degree centigrade 
 
µg/ml = microgram per milliliter 
 
µl = microlitre 
 
Acetyl-CoA = Acetyl coenzyme  
 
ACP = Acid phosphatase 
 
ADA CPR = American Diabetes Association Clinical Practice Recommendations 
 
ADP = Adenosine diphosphate 
 
ALP = Alkaline phosphatase 
 
AP = Andrographis paniculata 
 
AG = Andrographolide 
 
ANOVA = Analysis of variance 
 
ATP = Adenosine triphosphate 
 
AUC = Area under the curve 
 
BG = Blood glucose 
 
B.wt = body weight 
 
BSA = Bovine serum albumin 
 
cAMP = cyclic Adenosine monophosphate 
 
CB-1 = Cannabinoid receptor-1 
 
CCl4 = Carbon tetrachloride 
 
DNA = Deoxyribonuclueic acid 
 
CDC = Centre for Disease Control 
 
CV = Coefficient of variation 
 
 xvi 
DeAG = 14-deoxy-11,12-didehydroandrographolide 
 
DNA = Deoxyribonucleic acid 
 
DPP-IV = Dipeptidyl peptidase-IV  
 
DW = Distilled water 
 
FDA = Food and Drugs Administration 
 
FFA = Free fatty acids 
 
FPG = Fasting plasma glucose 
 
FSIVGTT = Frequently sampled intravenous glucose tolerance test 
 
GIP = Glucose-dependent insulinotropic polypeptide 
 
GLP-1 = Glucagon-like peptide-1  
 
GLUT 4 = Glucose transporter 4 
 
GK = Glucokinase 
 
G6P’Tase = Glucose 6 phosphatase 
 
G6PDH = Glucose 6 phosphate dehydrogenase 
 
GM-CSF = Granulocyte Macrophage-Colony Stimulating Factor 
 
GOT = Glutamate oxaloacetate transaminase 
 
GPT = Glutamate pyruvate transaminase  
 
GPx = Glutathione peroxidase 
 
GR = Glutathione reductase 
 
GSH = Glutathione S hydroxylase 
 
GST = Glutathione S tranferase 
 
HbA1c = Hemoglobin A1c 
 
HK = Hexokinase 
 
HPLC = High Performance Liquid Chromatography 
 
HPTLC = High Performance Thin Layer Chromatography 
 
 xvii 
Hrs = Hours 
 
HDL = High density lipoprotein 
 
HOMA = Homeostasis model assessment 
 
IFN-γ = Interferon-gamma 
 
IgG = Immunoglobin G 
 
IGT = Impaired glucose tolerance 
 
IRC = Insulin resistance control 
 
IL-1β = Interleukin-1-beta 
 
IL-6 = Interleukin-6 
 
ip = Intra peritoneal 
 
IPGTT = Intra peritoneal glucose tolerance test 
 
IRS-2 = Insulin receptor substrate-2 
 
LDH = Lactate dehydrogenase 
 
LP = Lipid peroxidation 
 
LDL = Low density lipoprotein 
 
LOD = Limit of detection 
 
LOQ = Limit of quantitation 
 
mg = milligram 
 
µg = microgram 
 
mNADH = mitochondrial NADH 
 
mRNA = messenger ribonucleic acid 
 
NAD+ = Oxidised NAD 
 
NADH = Nicotinamide adenine dinucleotide 
  
NDFS = National Diabetes Fact sheet 
 
NeAG = Neoandrographolide 
 
 xviii 
NO = Nitric oxide 
 
NC = Normal control 
 
NPH = Neutral Protamine Hagedorn 
 
OGTT = Oral glucose tolerance test 
 
PBG = Peak blood glucose 
 
PDM = Persetuan Diabetes Malaysia 
 
po =  peroral 
 
PG = Pioglitazone 
 
PKC-β = protein kinase C-beta 
 
PKC-ε = Protein kinase C-epsilon 
 
PPAR-γ = Peroxisome proliferator activated receptor- gamma 
 
PPG = Post prandial glucose 
 
PTP-1B = protein tyrosine phosphatase 1B 
 
ROS = Reactive oxygen species 
 
RP-HPLC = Reversed phase High performance liquid chromatography 
 
RSD = Relative standard deviation 
 
SEM = Standard error of mean 
 
SPSS = Statistical procedures for social sciences 
 
STZ = streptozotocin 
 
STZ-NA = streptozotocin-nicotinamide 
 
sc = subcutaneous 
 
T2DM = Type 2 Diabetes Mellitus  
 
TBARS = Thiobarbituric acid reacting substances 
 
TIMP-1 = Tissue inhibitor of metalloproteinase-1 
 
Trtmnt = Treatment 
 
 xix 
TNF-α = Tumour necrosis factor- alpha 
 
USP DI = United States Pharmacopoeia Drug information 
 
UV-VIS = Ultraviolet-Visible 
 
VEGF = Vasculoendothelial growth factor 
 
WHO = World Health Organisation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xx 
KESAN EKSTRAK ETANOL ANDROGRAPHIS PANICULATA 
KEATAS TIKUS DIABETIS MELLITUS JENIS 2 DAN RINTANG INSULIN  
 
ABSTRAK 
 
Kebanyakan kajian mengenai aktiviti antidiabetik Adrographis paniculata 
sebelum ini termasuk yang dilakukan oleh Kasmuri (2006) tertumpu kepada kesan 
tumbuhan tersebut keatas diabetis jenis I sedangkan lebih dari 98 % pesakit diabetis 
adalah dari jenis 2 (T2DM).  Oleh itu, tujuan kajian ini adalah untuk menilai kesan-
kesan ekstrak etanol A.  paniculata keatas tikus T2DM dan rintang insulin. 
 
Percubaan in vitro perencatan enzim alfa glukosidase dan alfa amilase 
menunjukan ekstrak etanol mempunyai kesan perencatan aktiviti alfa glucosidase 
yang nyata dan  perencatan alfa amilase yang lemah. Penemuan kajian ini disokong 
oleh ujian perencatan aktiviti alfa glukosidase akut in-vivo pada kedua-dua tikus 
normal dan tikus diabetik. Rawatan dengan ekstrak etanol 250,500 dan 1000 mg/kg 
menyebabkan penurunan puncak glukosa (PBG) dan kawasan di bawah keluk (AUC) 
dan oleh itu boleh merencat peningkatan PBG bila diberikan cabaran dengan kanji 
dan sukrosa.  
 
20%v/v 250,500, dan 1000mg/kg dan ekstrak etanol 95% v/v 500 dan 1000 
mg/kg tambahan pula, rawatan kronik dengan ekstrak etanol selama 21 hari dapat 
menurunkan paras glukosa serum tikus yang diaruhkan T2DM menggunakan 
nikotinamida dan streptozotosin. Didapati berlaku penurunan paras enzim 
glukoneogenik dan peningkatan paras enzim glikolitik dan lipogenik hati. Paras 
kolesterol, trigliserida, dan asid lemak bebas serum juga menurun. Disamping itu 
berlaku juga peningkatan kecil paras glutation S hidroksilase (GSH), glutation S 
transferase (GST), dan glutation reduktase (GR) hati diperkirakan akibat dari kesan 
 xxi 
antioksidatif. Keputusan percubaan  menyarankan pemberian ekstrak telah menekan 
glukoneogenesis dan glikogenesis dan seterusnya meningkatkan glikolysis dan 
glikogenesis. 
 
Akhirnya kesan pemberian ekstrak secara keronik selama 30 hari dinilai 
keatas tikus rintang insulin aruhan diet lemak dan streptozotosin. Pemerhatian 
menunjukan ekstrak etanol 20%v/v 500, dan 1000mg/kg ekstrak etanol dan 95% v/v 
500 dan 1000 mg/kg tambahan pula boleh menyegerakan pelupusan glukosa dari 
darah dan mengurangkan peningkatan AUC glukosa. Dalam ujian cabaran dengan 
tolbutamida, ekstrak didapati berupaya meningkatkan tindakbalas terhadap glukosa 
serum. Kesan kehilangan gerak balas terhadap tolbutamida telah di lambatkan pada 
tikus yang dirawat dengan ekstrak dan sterusnya melambatkan berlakunya 
kerintangan terhadap insulin. Kesan peningkatan kepekaan terhadap insulin oleh 
pemberian kronik ekstrak selama 30 hari  telah dinilaikan pada tikus diabetik aruhan 
streptozotosin. Keputusannya didapati pemberian ekstrak etanol 20%v/v tidak 
memberikan kesan terhadap kepekaan insulin, tetapi pemberian ekstrak etanol 
95%v/v  telah meningkatkan dengan sederhana kepekaan terhadap insulin 
sepertimana kesan metformin. 
 
Oleh itu aktiviti antidiabetik boleh diperantarakan secara bebas oleh 
mekanisme ekstra pancreas seperti yang ditunjukan oleh bertambah baiknya paras 
glukosa semasa berpuasa akibat dari perencatan glukosidase, perangsangan 
penggunaan glukosa perifer dengan memudahkan oksidasi dan penggunaannya, 
peningkatan kepekaan terhadap insulin atau kombinasi dari semua faktor diatas. 
Penemuan yang menggalakan ini  menjadikan ekstrak etanol A. paniculata 
 xxii 
berpotensi digunakan untuk merawat T2DM dan keadaan rintang insulin pada 
manusia. 
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EFFECT OF ETHANOLIC EXTRACTS OF Andrographis paniculata ON 
TYPE 2 DIABETES MELLITUS AND INSULIN RESISTANT RATS 
 
ABSTRACT 
 
Most of the previous studies on anti-diabetic activity of Andrographis 
paniuclata including the studies performed by Kasmuri (2006) were concentrating on 
the effect of the plant on Type-I diabetes whereas more than 98% of diabetics in the 
affected population are of the type 2 (T2DM) nature. Therefore, the aim of the 
present study was to evaluate the effects of ethanolic extracts of Andrographis 
paniculata on T2DM and insulin resistance rats.  
 
In vitro alpha glucosidase and alpha amylase enzyme inhibitory experiments 
demonstrated that both 20%v/v and 95% v/v ethanolic extracts have appreciable 
alpha glucosidase and a weak alpha amylase inhibitory activity. This finding was 
further supported by acute in vivo alpha glucosidase inhibitory test in diabetic rats. 
The ethanolic extracts treatment at doses of 250, 500, and 1000mg/kg caused a 
reduction in peak blood glucose (PBG), and area under the curve (AUC) levels and 
thus could inhibit the rise in PBG when challenged with starch, and sucrose.  
 
Furthermore, chronic treatment for 21 days with 250, 500 and 1000mg/kg of 
20%v/v ethanol extract and and 500, 1000mg/kg of 95% v/v ethanolic extracts 
reduced the fasting serum glucose levels of nicotinamide and streptozotocin-induced 
T2DM rats. There was a reduction in liver gluconeogenic enzyme level and an 
increase in liver glycolytic and lipogenic enzyme levels on treatment with 20%v/v 
ethanolic extract. The serum cholesterol, triglycerides, and free fatty acids were also 
reduced with both the extracts at all the doses. There was also a small increase in 
liver glutathione S hydroxylase (GSH), glutathione S transferase (GST), and 
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glutathione reductase (GR) enzyme activity suggesting an anti-oxidative effect. The 
results suggest that the 20% ethanolic extract may suppress gluconeogenesis and 
glycogenolysis with a subsequent increase in glycolysis and glycogenesis.  
 
Finally the effects of chronic treatment for 30 days with the extracts were 
evaluated in a fat-fed and low dose streptozotocin-induced insulin resistance rats. It 
was observed that the 500 and 1000 mg/kg doses of 20% v/v and 1000mg/kg dose of 
95% v/v ethanolic extract hastened the blood glucose disposal and reduced 
incremental glucose AUC. In the tolbutamide challenge test the same doses of both 
the extracts were observed to cause an increase in the serum glucose response. The 
loss of response to tolbutamide was delayed in extract treated groups thus effectively 
delaying insulin resistance. The insulin sensitising effect of the 30 days chronic 
treatment of the extracts was evaluated in streptozotocin-induced diabetic rats. It was 
found that 500 and 1000mg/kg doses of 20%v/v ethanolic extract had no insulin 
sensitising effect, while the 1000mg/kg dose of 95%v/v extract demonstrated a 
moderate insulin sensitising effect like metformin. 
 
Thus the anti-diabetic activity could be mediated independently by an extra 
pancreatic mechanism as shown by distinct improvement in fasting blood glucose 
levels due to alpha glucosidase inhibition, stimulation of peripheral glucose 
utilization by facilitating oxidation and utilization, increasing insulin senstivity or by 
a combination of all the above mechanisms. These promising findings make the 
ethanolic extracts of Andrographis paniculata, a good potential in the treatment of 
T2DM and insulin resistance cases in humans. 
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                                                    CHAPTER 1 
                                                    Introduction 
 
1.0. Type 2 Diabetes Mellitus and Insulin Resistance 
 
Type 2 diabetes mellitus (T2DM) is a progressive, chronic metabolic disorder 
notable for the underlying defects in carbohydrate and lipid metabolism. It is 
typically characterized by several sequential steps involving impaired beta cell 
function, resulting in a relative insulin deficiency, followed by insulin resistance with 
decreased glucose transport into muscle and fat cells, accompanied by unrestrained 
hepatic glucose output, all of which contribute to an overwhelming glycaemic status.  
 
World over, one of the major public health challenges of the 21st century is 
undisputedly T2DM. According to World Health Organisation (WHO) the epidemic 
of diabetes is strongly related to lifestyle and economic changes. Centre for Disease 
Control (CDC), Atlanta, US has projected data that shows approximately 200-300 
million people worldwide will have developed T2DM by 2025 (CDC, NDFS, 2002) 
meaning an increase of nearly 6 million patients every year. Diabetes is the third 
leading cause among some tribal populations in South East Asian countries. 
Uncontrolled T2DM is associated with long-term microvascular and macrovascular 
complications with failure of vital organs, leading to nephropathy, atherosclerosis, 
retinopathy, renal failure, neuropathy etc. Insulin resistance and beta cell dysfunction 
are fundamental defects known to precede the onset of T2DM. The first signs of beta 
cell dysfunction can be detected 10-12 years prior to a full blown presentation of 
T2DM. Hence there is room for enormous opportunities and various parameters to 
target above defects in order to attempt to prevent and cure T2DM. 
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1.1. Current scenario in Malaysia 
Diabetes is a growing health concern in Malaysia. The number of people with 
diabetes in Malaysia is increasing while complication rates and associated diseases 
amongst diabetics are significantly high. Occurrence of T2DM has also steadily 
increased over the years with an estimate of 0.65% in 1960, to 2% in 1982. In the 
National Health and Morbidity Survey (NHMS) carried out in 1986, the prevalence 
of diabetes mellitus was estimated to be 6.3%. In 1996, the Second National Health 
and Morbidity survey showed that the national prevalence of diabetes and impaired 
glucose tolerance in Malaysia were 8.3% and 4.8% respectively (Ooyub, 2004). In 
1999, based on the prevalence among adults aged 30 years and above, there were 
700,000 to 900,000 persons with diabetes. Currently there are around 1.2 million 
diabetics in Malaysia, with 98% of them diagnosed with T2DM. (PDM, 2007). This 
means there are approximately 8 diabetics in every 100 adults. The WHO has 
estimated that in 2030, Malaysia would have a total number of 2.48 million diabetics 
compared to 0.94 million in 2000 - a phenomenal 164% increase. 
   
Statistics from the Ministry of Health records also shows that the number of 
admissions to Government Hospitals in Peninsular Malaysia for diabetes mellitus 
had increased (PDM, 2007).Admission to hospitals due to diabetes has increased 
from 19,629 cases in 1991 to 30,661 cases in 2001, which shows an increase of 56% 
over a span of 10 years. Mortality due to diabetes has also increased from 254 deaths 
in 1991 to 380 deaths in 2001 which is an increase of 50%. 
 
Hospital-based data indicate complication rate as high as 50% (Mustaffa, 
1983). Associated hypertension was seen in 10-20% of diabetics and, 
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hypercholesterolemia in 29% of patients. In one study, 38% were noted to have 
multiple complications, the commonest being hypertension and stroke, and gangrene 
with neuropathy. One reason for the high complication rates is poor glycaemic 
control. The Diabetes Care Data Collection Project (DCDCP) (Mustaffa, 1983) 
conducted in 1997 showed that more than half of diabetic patients were poorly 
controlled where 73% had HbA1c more than 7.5% and 68% had fasting blood glucose 
more than 7.8 mmol/l. Few number of patients were monitored for renal function 
where only 30% were examined for proteinuria and only 1% were examined for 
microproteinuria. Eye examination was performed in only 3-20% while feet 
examination was conducted in 6-11% of cases. Glucose self-monitoring rate was less 
than 1%. The most prevalent chronic complications were neuropathy (58%) and 
retinopathy (53%). 
Diabetes mellitus is strongly associated with obesity and the rise in the 
prevalence of diabetes is due to a rise in the prevalence of obesity. In the NHMS 2, 
1996, the prevalence of obesity was 4.4% and of overweight was 16.6%. Amongst 
those with diabetes mellitus, 18.8% were either obese or overweight. In a study in 
Kelantan, 38.4% of diabetics were either obese or overweight compared to 24.1% in 
those with normal glucose tolerance (Mafauzy, 2006).  
1.2. Pathophysiology of type 2 diabetes mellitus 
 
 T2DM affects more than 90% of all adults with diabetes, is a complex 
metabolic disease, characterised by elevated serum glucose levels (ADA, CPR, 
2004). Fasting hyperglycaemia is caused by uncontrolled basal hepatic glucose 
output, an upshot of hepatic resistance to insulin action. Post-prandial 
hyperglycaemia results from abnormal insulin secretion by beta cells in response to 
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food, and a increase in hepatic glucose production, and defective glucose uptake by 
peripheral insulin-sensitive tissues. Chronic hyperglycaemia further impairs beta cell 
secretory kinetics and tissue sensitivity to insulin, known as glucotoxicity (Dailey, 
2004). Thus, both impaired insulin action (insulin resistance) and impaired insulin 
secretion (insulin deficiency) are central to the pathogenesis of T2DM. Figure.1.1 
represents pathogenesis of T2DM. 
 
Figure 1.1   Pathogenesis of type 2 diabetes mellitus. Sites of action of oral agents 
are indicated. A negative sign indicates inhibition; a positive sign 
indicates stimulation. (DeFronzo, 1999) 
 
  
On ingesting food, maintenance of normal glucose tolerance depends on t he 
following three events in sync: 1) stimulation of insulin secretion; 2) insulin-
mediated control of endogenous (primarily hepatic) glucose production by the 
resultant hyperinsulinemia; and 3) insulin-mediated stimulation of glucose uptake by 
peripheral tissues (primarily muscle). To a lesser extent, hyperglycemia can also 
independently suppress hepatic glucose production and enhance muscle glucose 
uptake. Accelerated gluconeogenesis is the major abnormality responsible for the 
increased rate of basal hepatic glucose production (Magnusson, 1992). The increased 
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rate of basal hepatic glucose production closely correlates with the increase in fasting 
serum glucose level. Since the fasting plasma glucose level is the major determinant 
of the mean day-long serum glucose level (clinically indicated by hemoglobin A1c 
[HbA1c] value), agents that reduce the elevated basal rate of hepatic glucose 
production will be especially effective in improving glycemic control. Muscle tissue 
in T2DM patients is resistant to insulin (DeFronzo, 1997; Bonadonna et al, 1996). 
Defects in insulin receptor function, insulin receptor-signal transduction pathway, 
glucose transport and phosphorylation, glycogen synthesis, and glucose oxidation all 
contribute to muscle insulin resistance (DeFronzo, 1997). In response to food, the 
ability of endogenously secreted insulin to boost muscle glucose uptake is markedly 
impaired (Mitrakou et al, 1990; Ferrannini et al, 1998). Hence muscle insulin 
resistance and impaired suppression of hepatic glucose production contribute equally 
to the excessive postprandial increase in the plasma glucose level (Ferrannini et al, 
1998). So it is logical to expect that drugs causing an improvement in muscle insulin 
sensitivity will be effective in decreasing the excessive increase in plasma glucose 
level after carbohydrate ingestion. 
 
Impaired insulin secretion also plays a major role in the pathogenesis of 
glucose intolerance in patients with T2DM (Polonsky, 1995). In the cascade of 
events, leading to full blown diabetes mellitus, all T2DM patients with elevated 
fasting serum glucose levels have a defect in insulin secretion (Polonsky, 1995). In 
diabetic patients with mild fasting hyperglycemia (glucose level, 7.8 mmol/l [140 
mg/dl]), serum insulin levels during an oral glucose tolerance test or a mixed meal 
usually are elevated. As the fasting serum glucose level increases to more than 7.8 
mmol/l, insulin secretion decreases progressively, and all diabetic patients with a 
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fasting serum glucose levels above 10.0-11.1 mmol/l (180-200 mg/dl) have a 
deficient serum insulin response. It follows, therefore, that drugs that improve insulin 
secretion will be effective in treating T2DM. In summary, patients with T2DM are 
characterized by defects in both insulin secretion and insulin action.  
 
Maintaining serum glucose concentrations near the normal range by using 
insulin or oral antidiabetic agents has been demonstrated to prevent or delay the 
development of long term complications of T2DM  (Lawrence, 2005). Weight 
control and physical activity are the predominant and effective non pharmacological 
ways to treat borderline type 2 diabetics. So it is common to switch over to 
pharmacological approaches at one point of time when non pharmacological 
interventions are ineffective in maintaining strict glycemic controls. 
 
1.3. Clinical features of type 2 diabetes mellitus 
A fasting serum glucose level above 7 mmol/l (126 mg/dl) on at least two 
occasions or random serum glucose of more then 11.1 mmol/l (200 mg/dl) with 
symptoms of polyuria and polydipsia are diagnostic indicators of T2DM (Nathan, 
2002; Ahmann and Riddle, 2002). Subjects with impaired fasting serum glucose 
levels are often given an oral glucose tolerance test administered in the fasted state 
with consumption of a measured amount of a high glucose drink. Based on the 
excretion of glucose, with respect to time, individuals are grouped into three classes:  
normal, impaired, and diabetic.  
 
A common management scheme may not be optimal for a disease with 
multifactorial causes. For borderline T2DM subjects, physicians usually recommend 
diet control and an increase in physical activity, but only ~20% of patients are 
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benefited by these interventions (Koro, 2004). The patients not helped by diet and 
exercise alone, or those who present with severe symptoms, are treated with one or 
more of 6 classes of drugs. These drugs target different pathways and organs: insulin 
secretion by the pancreas (sulfonylurea and meglitinides), glucose absorption by the 
intestines (alpha glucosidase inhibitors), glucose production in the liver (metformin), 
and insulin sensitivity in adipose and peripheral tissues (e.g., rosiglitazone and 
pioglitazone). A newly approved agonist of glucagon-like-peptide 1, exenatide, also 
acts in the pancreas to stimulate insulin production (Kwon, 2004), only when serum 
glucose levels are high. Approximately 50% of T2DM patients are prescribed oral 
medications only, about 11% prescribed combinations of oral agents with insulin, 
and the remainder takes no medications (20%) or insulin alone (16.4%) (Koro, 
2004). Thus, current medical management of T2DM can be a lengthy trial and error 
method, involving significant amount of time and considerable expense. 
 
1.4. Insulin resistance 
Insulin resistance is said to be present when the biological effects of insulin 
are less than expected for both glucose disposal in skeletal muscle and suppression of 
endogenous glucose production primarily in the liver (Dinneen, 1992). In the fasting 
state, however, muscle accounts for only a small proportion of glucose disposal (less 
than 20%) whereas endogenous glucose production is responsible for all the glucose 
entering the plasma. Endogenous glucose production is accelerated in T2DM or 
impaired fasting glucose patients (Weyer, 1999; Meyer et al, 1998). Since this 
increase occurs in the presence of hyperinsulinaemia, at least in the early and 
intermediate disease stages, hepatic insulin resistance becomes the driving force of 
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hyperglycaemia of type 2 diabetes. Figure 1.2 shows clinical and laboratory 
abnormalities associated with insulin resistance. 
 
   Figure 1.2 Clinical abnormalities in insulin resistance (Cefalu, 2001). 
 
 
1.5. Causative factors of insulin resistance 
The combination of excess caloric intake and relatively scarce physical 
activity, with the inherent traits of obesity, can induce a state of resistance to the 
action of insulin (Kahn, 2003). Insulin resistance is an important component of the 
metabolic syndrome, a clinical syndrome in which a cluster of confounding factors 
such as obesity, dyslipidemia, and hypertension leads to a substantial increase in 
cardiovascular risk (Haffner, 1990). Insulin resistance is also a crucially important 
metabolic abnormality in T2DM, and overt diabetes is thought to be preceded by a 
long period of insulin resistance, during which blood glucose is maintained near 
normal levels by compensatory hyperinsulinemia (Kahn, 2003). 
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When beta cells are no longer able to compensate for insulin resistance by 
adequately increasing insulin production, impaired glucose tolerance (IGT) appears 
(Kahn, 2003). This condition is characterized by an excessive blood glucose 
concentration in the postprandial phase, with fasting glucose being in the normal 
range (Kahn, 2003). Persistence of imbalance between caloric intake and expenditure 
eventually leads to overt diabetes, characterized by high glycemic status in any 
condition whether fasting or postprandial. 
 
1.6. Pathogenesis of insulin resistance  
The most important tissues involved in the pathogenesis of insulin resistance 
are muscle and adipose tissue. When caloric intake exceeds the energy expenditure, 
the substrate-induced increase in citric acid cycle activity generates an excess of 
mitochondrial NADH (mNADH) and reactive oxygen species (ROS) (Maddux, 
2001). Hence cells may reduce the formation of ROS and/or enhance ROS removal. 
Prevention of ROS formation is accomplished by preventing the build-up of 
mNADH by inhibiting insulin stimulated nutrient uptake and preventing the entrance 
of energetic substrates (pyruvate, fatty acids) into the mitochondria. 
 
Influx of substrates into the citric acid cycle generates mitochondrial acetyl-
CoA and NADH (Maddux, 2001). Acetyl-CoA, derived either from glucose through 
pyruvate or from beta-oxidation of free fatty acids (FFA), combines with 
oxaloacetate to form citrate, which enters the citric acid cycle and is converted to 
isocitrate. NAD+-dependent isocitrate dehydrogenase generates NADH. When 
excessive NADH cannot be dissipated by oxidative phosphorylation (or other 
mechanisms), the mitochondrial proton gradient increases and single electrons are 
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transferred to oxygen, leading to the formation of free radicals, particularly 
superoxide anion (Maechler, 1999). The generation of excessive NADH may be 
prevented in several ways, one of which is the inhibition of FFA oxidation 
(Williamson and Cooper, 1980). An increase in intracellular FFA, in turn, leads to 
reduced GLUT4 translocation to the plasma membrane, resulting in resistance to 
insulin stimulated glucose uptake in muscle and adipose tissue (Tretter and Vizi, 
2000; Rudich, 1998; Tailor, 2003). Here insulin resistance may be considered a 
compensatory mechanism that protects the cells against further insulin stimulated 
glucose and fatty acid uptake and therefore oxidative damage. 
 
Initially, insulin resistance is compensated by hyperinsulinemia through 
which a normal glucose tolerance is preserved. Deterioration to IGT occur when 
insulin resistance increases further and/or the compensatory insulin secretory 
response decreases. An increase in insulin, FFA, and/or glucose levels can increase 
ROS production and oxidative stress, as well as activate stress-sensitive pathways. 
This, in turn, can worsen both insulin action and secretion, thereby accelerating the 
progression to overt type 2 diabetes. 
 
1.7. Drug therapy in the treatment of type 2 diabetes mellitus and insulin      
resistance  
 Antidiabetics like sulphonylureas, biguanides, meglitinides, 
thiazolidinediones, and insulin have been the mainstays of treatment for type 2 
diabetes mellitus and insulin resistance and are still in active use. Monotherapy for 
T2DM may fail with time as disease progresses this is when combination therapy is 
useful. Generally two different classes of drugs may be added with differing 
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mechanism of action thus promoting synergism with better control of symptoms. So 
coexisting disease conditions such as hypertension, high cholesterol levels, obesity, 
and potential for cardiovascular disease or complications must be taken into 
consideration before prescribing a combination therapy. The combination therapy 
most commonly prescribed are: sulphonyurea e.g. glyburide, glimepiride) with 
metformin, troglitazone with a sulphonylurea (glyburide) / insulin or pioglitazone 
with a sulphonylurea/ insulin, repaglinide with metformin, insulin (NPH) with a 
sulphonylurea.  
 
Figure 1.3 Mechanism of action of oral antidiabetic drugs. (Matthaei, 2000). 
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1.8. Problems of antidiabetic therapy 
Though the oral antidiabetic therapy are found to be relatively safe and 
effective in type 2 diabetes and insulin resistance, each drug has its own range of side 
effects which may compromise the disease status or even worsen the condition in 
some cases (for example weight gain of sulphonylureas). Considering the fact that 
T2DM is a progressive disease with varied symptoms at each stage, treatment is also 
complicated, and usually the patients are prescribed with a combination of drugs 
once the disease attains a more chronic state. Some of the side effects which may 
offset the benefit from the therapy are as follows:  
 
 Weight gain, hyperinsulinemia, and tolerance of sulphonylureas.  
 Modest weight gain on treatment with meglitinides. 
 Weight gain, edema, volume expansion on treatment with thiazolidinediones. 
 
 Weight gain, patient non-compliance with insulin injections. 
 
The last few years have been stagnant as far as new therapeutic options for 
oral agent for patients with T2DM are concerned and clearly there is a need for some 
newer specific and effective agents with action on multiple targets. Over the next 
several years, as the results of key clinical trials are revealed, the optimal therapeutic 
approach will likely be better defined, specifically regarding the best initial therapy 
for borderline and full blown T2DM patients. Such a choice may arise from studies 
exploring the cardiovascular and beta cell impact of various agents, particularly the 
insulin sensitizers (Kimmel and Inzucchi, 2005). Moreover new formulations of 
insulin such as for oral therapy, inhalational routes etc are finding success in research 
studies and also commercially, though limited. In the near future use of insulin in 
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various novel drug delivery systems will be a reality. Further, emerging concepts to 
be addressed may involve the progression to combination strategies in the pre-
diabetic state, and liberal use of novel insulin formulations sooner in the disease 
course.  
 
Obesity, the principle cause of type 2 diabetes, remains an important target 
for possible drug therapy. Available anti-obesity drugs have limited effectiveness on 
body weight; clearly, newer therapeutic options are needed (Kimmel and Inzucchi, 
2005). Hence rimonabant-like drugs modulating the endogenous cannabinoid system 
and weight loss agents with more substantive effects on body weight will play an 
increasingly important role in the future therapy of obese T2DM patients. 
Availability of new information about safety, efficacy, and tolerability of newer 
agents from diabetic clinical trials that would significantly affect the way drugs are 
prescribed is eagerly awaited. 
 
1.9. Current drugs in the pipeline  
 
1.9.1 Exenatide 
 
Exenatide (Byetta®), a synthetic version of the naturally occurring peptide 
exendin-4, has recently been approved by the US Food and Drug Administration 
(FDA) for the treatment of type 2 diabetes. It is a potent agonist of the glucagon-like 
peptide-1 (GLP-1) receptor, which acts primarily to reduce postprandial glucose 
excursions, with a lesser effect on fasting plasma glucose (FPG) levels (Drucker, 
2001).  
 
GLP-1 is an important incretin hormone whose secretion is reduced in 
individuals with type 2 diabetes. GLP-1 stimulates the secretion of insulin and 
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inhibits the secretion of glucagon in a glucose-dependent manner, dramatically 
lowering postprandial glucose levels (Drucker, 2001; Vilsboll, 2001), and regulates 
nutrient intake via effects on gastric emptying and feeding behaviour (Nauck et al, 
1996; Turton et al, 1996). Therefore, a key benefit of GLP-1 mimetics may be 
improved glycaemic control with a decreased incidence of hypoglycemia relative to 
that observed with agents such as sulphonylureas and insulin, which act 
independently of glucose concentrations. GLP-1 is rapidly metabolised by dipeptidyl 
peptidase-IV (DPP-IV) immediately within few minutes of release thus limiting 
activity, necessitating the development of synthetic analogues or agonists. Exenatide 
is resistant to degradation by DPP-IV, with a half-life of 2-4 hrs, and is suited to 
twice daily injection. In clinical trials, it was administered at a dose of 10 µg twice a 
day for 82 weeks demonstrated a mean improvement in HbA1c of 1.1% from baseline 
(Buse, 2004) with 4.5 kg mean weight reduction (Buse, 2004; DeFronzo, 2005; 
Kendall et al, 2005; Geelhoed-Duijvestijn, 2007).  
 
The most frequent adverse event associated with exenatide therapy was 
nausea, which was generally mild or moderate in intensity and peaked during the 
initial weeks of dosing (weeks 0-8), before decreasing in incidence (Buse, 2004; 
DeFronzo, 2005; Kendall  et al, 2005). 
 
1.9.2. Pramlintide 
 
Pramlintide (Symlin®) is an amylin analogue that is approved by the FDA for 
treatment of types 1 and 2 diabetes in patients who use mealtime insulin. Amylin is a 
peptide hormone that is co-secreted with insulin from the pancreatic beta cell and is 
therefore deficient in individuals with diabetes. It inhibits glucagon secretion, delays 
gastric emptying, and acts to enhance satiety. Natural amylin is liable to aggregate 
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and form amyloid fibres, which may play a part in beta cell destruction in type 2 
diabetes, making it unsuitable for therapeutic use. Therefore, synthetic analogues 
have been developed that do not possess this characteristic (Schmitz, 2004). It is 
administered by subcutaneous injection prior to meals, in order to specifically reduce 
postprandial glucose levels. 
 
Addition of pramlintide to insulin, metformin and sulphonylureas has 
demonstrated significantly reduced HbA1c values from baseline compared with 
placebo. Additionally there was a slight decrease in body weight compared with an 
increase in body weight with placebo. The common side effects of pramlintide 
therapy are nausea and vomiting. 
 
 
1.9.3. Rimonabant  
 
FDA has approved rimonabant (Acomplia®) for obesity, metabolic disorders 
associated with diabetic conditions. It is first in class of novel cannabinoid receptor-1 
antagonists (CB-1). The endocannabinoid system influences food intake by 
modulating the major ‘reward’ pathway in the mesolimbic dopaminergic system of 
the brain (Schlicker and Kathmann, 2001). Endogenous cannabinoids of the 
hippocampus and nucleus accumbens are involved in driving appetite for palatable 
food and therefore determine total energy intake and the severity of diet-induced 
obesity (Harrold, 2002). In clinical trials, rimonabant at a dose of 20 mg/day with 
sulphonylurea or metformin caused a decline in HbA1c levels by 0.7% with effective 
reductions in weight reduction and waist circumference. Additionally HDL levels 
increased with simultaneous reduction in triglyceride levels (Scheen, 2005). The 
commonly encountered side effects at that dose were increased incidence of 
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psychiatric disturbances, such as depression and anxiety, compared with placebo 
(Despres, 2005; Vaan Gaal, 2005). 
 
1.9.4. Vildagliptin 
Vildagliptin (Galvus®) is a DPP-IV inhibitor, has completed Phase III clinical 
development and awaiting FDA approval for marketing. DPP-IV inhibitors act to 
extend the half-life of endogenous GLP-1 by blocking its degradation. Newer DPP-
IV inhibitors in clinical development are administered orally, once daily, a potential 
advantage over the injectable GLP-1 agonists. In a clinical study vildagliptin was 
dosed at 50 mg once-daily in addition to metformin therapy in patients not achieving 
adequate glycaemic control. Patients receiving the combination showed significant 
reductions in both HbA1c and fasting plasma glucose concentrations compared to 
placebo and vildagliptin did not significantly alter body weight (Ahren, 2004). 
 
1.9.5. Ruboxistaurin 
Ruboxistaurin (to be named Arxxant®) is a selective inhibitor of protein 
kinase C-beta (PKC-beta) that has been assessed in Phase III clinical studies for the 
treatment of diabetic retinopathy, nephropathy and neuropathy. Currently FDA has 
requested additional efficacy data to support the clinical evidence. Hyperglycaemia 
activates PKC-beta, and is associated with the development of microvascular 
complications in the retina, kidney and nervous system. These complex clinical 
sequelae are believed to be mediated by various mechanisms involving inflammatory 
mediators, endothelial activation and endothelial proliferation (Koya and King, 
1998). 
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In a study of 252 patients with diabetic retinopathy, ruboxistaurin (8, 16 or 32 
mg/day) did not prevent progression of the disease, but significantly delayed the 
occurrence of moderate visual loss (PKC-DRS, 2005).  
 
1.9.6. Sitagliptin 
Sitagliptin (Januvia®) orally-active inhibitor of the dipeptidyl peptidase-IV 
(DPP- IV) enzyme recently approved for marketing by FDA and is believed to exert 
its actions in patients with T2DM by slowing the inactivation of incretin hormones. 
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control 
in patients with T2DM. It is also indicated as combination therapy in patients with 
T2DM to improve glycemic control in combination with metformin or a PPAR-γ 
agonist (e.g., thiazolidinediones) when the single agent alone, with diet and exercise, 
does not provide adequate glycemic control (Sitagliptin, 2006). 
 
Incretins, like glucagon-like peptide-1 (GLP-1) and glucose-dependent 
insulinotropic polypeptide (GIP), are released by the intestine throughout the day, 
and levels are increased in response to food. These hormones are rapidly inactivated 
by DPP-IV enzyme. The incretins are part of an endogenous system involved in the 
physiologic regulation of glucose homeostasis. When blood glucose concentrations 
are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from 
pancreatic beta cells by intracellular signalling pathways involving cyclic AMP. 
GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduced 
hepatic glucose production. By increasing and prolonging active incretin levels, 
sitagliptin increases insulin release and decreases glucagon levels in the circulation in 
a glucose-dependent manner.  
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In patients with type 2 diabetes, treatment with sitagliptin produced clinically 
significant improvements in HbA1c, fasting plasma glucose (FPG) and 2-hour post-
prandial glucose (PPG) compared to placebo. In a safety and efficacy study as 
monotherapy sitagliptin at 100 mg daily provided significant improvements in 
HbA1C, FPG, and 2-hour PPG compared to placebo (Sitagliptin, 2006). The 
commonly encountered side effects were upper respiratory tract infection, stuffy or 
runny nose and sore throat, headache. 
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CHAPTER 2 
Review of literature 
 
2.0. Andrographis paniculata 
 
2.1. Classification 
 
Kingdom : Plantae 
Division: Angiospermae 
Class: Dicotyledoneae 
Order: Tubiflorae 
Family : Acanthaceae 
Genus: Andrographis 
Species: paniculata Nees 
 
2.2. Botanical Description 
 
Andrographis paniculata (Burm.f.) Nees (Acanthaceae) is a traditional 
medicinal plant common in South East Asia and found from India to Indo-China. It is 
commonly called as king of bitter, kariyat, kalmegh, hempedu bumi and pokok cerita 
etc. It is an annual, erect and branched plant with lanceolate green leaves and attains 
heights of 60-70 cm. Since it is a traditional medicinal plant as usual it has various 
claims of uses and often with no literature supports, hence become difficult to verify. 
The leaves and aerial parts of the plant have been used to cure various kinds of 
ailments. Some of the uses are as follows: anti-pyretic, anti-periodic, anti-
inflammatory, expectorant, depurative, sudoforic, anti-helminthic, digestive and 
stomachic. It is useful in hyperdypsia, burning sensation, wounds, ulcers, chronic 
fever, malarial and intermittent fevers, inflammations, cough, bronchitis, skin 
diseases, leprosy, pruritis, intestinal worms dyspepsia, flatulence colic, diarrhoea, 
dysentery, and hemorrhoid 
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                 Figure 2.1 Leaves and aerial parts of Andrographis paniculata 
 
Expressed juice of the leaves of Andrographis paniculata Nees alone or 
together with cardamom, cloves and cinnamon made into little globules that are 
prescribed as a domestic remedy for common conditions such as griping, irregular 
stools, loss of appetite, flatulence, and diarrhoea of children. Decoction or infusion of 
the leaves has been used in conditions of sluggish liver, neuralgia, certain forms of 
dyspepsia associated with gaseous distension of the bowels, in general debility, in 
convalescence after fevers and in advanced stages of dysentery. During epidemic of 
influenza, a tincture of the plant is highly efficacious in arresting the progress of the 
disease. The herb is also reported to possess astringent, anodyne, tonic and is helpful 
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in dysentery, cholera, diabetes, influenza, bronchitis, swellings, itches, piles and 
gonorrhoea. A decoction of the plant is used a blood-purifier. It is used as a cure for 
torpid liver and jaundice. A decoction or infusion of the leaves is useful in general 
debility and dyspepsia. The leaves and roots are also used as febrifuge, tonic, 
stomachic, cholagogue and anti-helminthic. It is used indigenously in medicine 
particularly as bitter tonic, curing fevers, dysentery and eliminating intestinal worms. 
It is also used as cholagogue. The plant is used to relieve griping, irregular stools and 
loss of appetite in case of infants and in debility and certain forms of dyspepsia. It is 
also reported to heal peptic ulcer. 
 
2.3. Literature on Andrographis paniculata 
 
One of the earliest known reports mentioning several traditional uses of 
Andrographis paniculata is that of Nadkarni and Nadkarni, 1976 which indicates 
several uses of Andrographis paniculata. These uses were practiced in ancient 
Ayurveda for the cure of several ailments notable among them being anti-pruretic, 
anti-inflammatory, anti-diarrheal and as laxative, expectorant, depurative etc. It is 
also used in diseases of infectious origin like malaria and dysentery. 
 
Ancient Chinese physicians used it to treat inflammatory conditions, fever, 
cold, laryngitis and has been described as a cold property herb to get rid of body heat 
and dispose toxins from body (Deng, 1982). Dutta and Sukul, 1982 reported the anti-
inflammatory activity of deoxyandrographolide, andrographolide, and 
neoandrographolide from Andrographis paniculata leaf powder in rats. 
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According to the study conducted by Shahid, 1987 pretreatment with 
Andrographis paniculata aqueous extract demonstrated significant hepatoprotective 
effect in the invivo study as evidenced by the subsequent histopathology and liver 
enzyme levels. Further hepatoprotective study of andrographolide (the major active 
diterpenoid lactone of the plant Andrographis paniculata) was studied on acute 
hepatitis by Handa and Sharma, (1990a) induced in rats by a single dose of 
galactosamine (800 mg/kg, ip) and paracetamol (3 g/kg, po). Results indicated pre-
treatment and post-treatment of rats at different time intervals with different doses of 
andrographolide in the two experimental models of hepatotoxicity lead to complete 
normalisation of toxin-induced increase in the levels of all the five biochemical 
parameters and significantly ameliorated toxin-induced histopathological changes in 
the livers of experimental rats. The results confirmed the in vivo hepatoprotective 
effect of andrographolide against galactosamine or paracetamol-induced 
hepatotoxicity in rats. 
 
Another anti-hepatotoxic study of andrographolide (100 mg/kg, ip) was 
carried out by Handa and Sharma, (1990b) comparing the activity of 861.33 mg/kg, 
ip, of the methanolic extract (equivalent to 100 mg/kg of andrographolide) and 
761.33 mg/kg, ip, of the andrographolide-free methanolic extract (equivalent to 
861.33 mg/kg of the methanolic extract) of the plant, in CCl4-induced liver damage 
in rats. Biochemical parameters like serum transaminases- GOT and GPT, serum 
alkaline phosphatase, serum bilirubin and hepatic triglycerides were estimated to 
assess the liver function. Overall inhibition of CCl4-induced increase in the five 
biochemical parameters was found to be 48.6% (andrographolide), 32% (methanolic 
extract) and 15% (andrographolide-free methanolic extract) and 15% 
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(andrographolide free methanolic extracts). Andrographolide (100 mg/kg, ip) was 
also found to normalize completely the CCl4-induced increase in the pentobarbitone 
induced sleep time of mice. The results suggest that andrographolide is the major 
active anti-hepatotoxic principle present in Andrographis paniculata. 
 
Alcoholic extract of the leaves of Andrographis paniculata obtained by cold 
maceration at a dose of 300 mg/kg was selected to study hepatoprotective action 
against CCl4-induced liver damage. The extract was found to be effective in 
preventing liver damage which was evident by morphological, biochemical and 
functional parameters (Rana and Avadhoot, 1991). 
 
Study conducted by Visen, 1991 showed that andrographolide produced a 
dose (1.5-12 mg/kg, 7 days once daily) dependent choleretic activity in conscious rat 
as well as anaesthetized guinea pig. It also showed a significant anti-cholestatic 
effect (40-100%) against galactosamine induced hepatic damage. The compound 
showed significant anticholestatic effect (40-100%) against galactosamine induced 
hepatic damage. It also showed a significant hepatoprotective activity (20-100%) by 
increasing the viability of hepatocytes as tested by trypan blue exclusion and oxygen 
uptake tests. Andrographolide reversed the altered values of GOT, GPT and alkaline 
phosphatase in hepatocytes and serum. Andrographolide was found to be more 
potent than silymarin, a known hepatoprotective drug. 
 
The effect of crude ethanol extract of Andrographis paniculata was studied 
on experimental parasitaemia. A four-day suppressive test against Plasmodium 
berghei NK 65 in Mastomys natalensis (Misra, 1992) was carried out. The crude 
 24 
ethanol extract and the fractions reduced the level of parasitaemic load, but not in a 
dose-dependent manner. Chemoprophylactic activity of neoandrographolide was 
tested using different protocols. Pretreatment for 15 days with neoandrographolide 
before infection suppressed the parasitaemia. 
 
In another study on the alcohol extract of Andrographis paniculata (25 
mg/kg) and two of its constituent diterpenes andrographolide and 
neoandrographolide (6 mg/kg/day for two weeks) showed significant antihepatotoxic 
action in Plasmodium berghei K173-induced hepatic damage in Mastomys natalensis 
(Chander, 1995). The increased levels of serum lipoprotein-X, alkaline phosphatase, 
GOT, GPT and bilirubin were markedly reduced by Andrographis paniculata and its 
diterpenes. In the liver, the extract and its constituents decreased the levels of lipid 
peroxidation products and faciliated the recovery of superoxide dismutase and 
glycogen. The protective effects of andrographolide were comparable to those of 
neoandrographolide. 
 
Oral administration of andrographolide isolated from Andrographis 
paniculata leaves, (30, 100, and 300 mg/kg) was studied for its analgesic, anti-
pyretic and anti-ulcerogenic activities (Madav, 1995). Andrographolide did not show 
any analgesic activity in hot plate test in mice while it showed significant analgesic 
activity in acetic acid-induced writhing in mice and Randall Selitto’s test in rats at 
300 mg/kg dose. Andrographolide (100 and 300 mg/kg, po) produced significant 
(p<0.05) anti-pyretic effect after 3 hrs of administration in Brewer’s yeast-induced 
pyrexia in rats. Andrographolide also exhibited significant anti-ulcerogenic activity 
at 100 and 300 mg/kg doses in aspirin- induced gastric-ulceration experiment in rats. 
